Selank: Evidence, Mechanism, Dosing & Legal Status

Selank (TP-7) is a synthetic seven-amino-acid analog of the endogenous immunopeptide tuftsin, engineered in the 1990s at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is marketed in Russia as a non-sedating anxiolytic and is popular in nootropic circles for anxiety and focus; its human proof is real but narrow. This monograph separates what is shown in people from what is shown only in rodents.3

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. Selank is not an FDA-approved drug in the US; it is sold as a "research chemical not for human use" and should be treated as prohibited in sport. Dosing figures are reported strictly as seen in the published literature and Russian clinical practice for completeness — not as recommendations. Consult a licensed clinician before any health decision.

What is Selank and how does it work?

Selank is the heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro (MW approximately 751.9 Da). Its first four residues (Thr-Lys-Pro-Arg) are tuftsin, a natural fragment of the IgG heavy chain with immunomodulatory activity; the C-terminal Pro-Gly-Pro tripeptide was appended to slow enzymatic degradation and prolong action.3 The parent peptide has a very short plasma half-life of minutes, so oral dosing is ineffective because of gastric proteolysis, and intranasal administration is used clinically to reach the central nervous system; downstream transcriptional and enkephalinase effects outlast the parent molecule by hours.8 Precise nasal-bioavailability figures circulating online trace to vendor pages rather than a primary pharmacokinetic paper and should be treated as unverified.

The mechanism rests on four converging strands, most of them preclinical. First, Selank (and its sibling Semax) inhibit enkephalin-degrading enzymes in human serum, slowing breakdown of endogenous Leu- and Met-enkephalin and raising enkephalinergic tone — proposed as the core of its anxiolytic action. In the human anxiety trial, baseline Leu-enkephalin half-life was reduced and correlated with illness severity, then rose during Selank treatment, supporting an enkephalin-stabilizing mechanism in people.1 Second, a single intranasal dose in rat frontal cortex altered expression of GABA-A receptor subunits and transporters, a pattern suggesting Selank acts as an indirect, allosteric modulator of the GABA-A system rather than a direct GABA-site agonist; a delayed rise in the orexin precursor was proposed as a reason Selank lacks benzodiazepine-type sedation.3 Third, intranasal Selank increased hippocampal BDNF messenger RNA and protein in rats, linking it to synaptic-plasticity pathways.6 Fourth, rodent work reports increased serotonin tone and selective induction of interferon-alpha without changes in IL-4, IL-10 or TNF-alpha — a narrow, antiviral-leaning immunomodulation consistent with its tuftsin lineage.7 A human resting-state fMRI study in 52 healthy volunteers found Selank altered functional connectivity between the right amygdala and right temporal cortex, a plausible neural correlate of an anxiolytic effect.4

What is the evidence by indication?

The human dataset is small, largely Russian-language and single-region, while the mechanism is supported mainly by rodent transcriptomic and biochemical work. The table below grades each indication honestly.

The pivotal human study is a Russian comparative trial in 62 patients (Selank 30, medazepam 32) with generalized anxiety disorder and neurasthenia, using Hamilton, Zung and CGI scales plus serum enkephalin assays. Anxiolytic efficacy was similar to medazepam, with Selank additionally showing antiasthenic and mild psychostimulant effects and no sedation or cognitive impairment.1 Secondary write-ups credit Selank with benzodiazepine-level anxiolysis "without dependence or withdrawal," but these rest on the same small dataset, and per-arm response figures vary across summaries.2 No large, independent, placebo-controlled Western RCT and no meta-analysis exist, which is why the grade is B, not A. The interested reader can confirm there is no registered large Selank anxiety RCT by searching ClinicalTrials.gov, where the compound is conspicuously absent from major Western trial registries.

What doses appear in the literature?

Reported strictly as information, not a protocol. Selank is marketed in Russia as a 0.15% intranasal solution. In the generalized-anxiety and neurasthenia literature, dosing is on the order of about 300 micrograms per day intranasally, commonly divided across two or three doses, over courses of roughly 10 to 14 days.1 Oral administration is reported ineffective because of gastrointestinal peptide degradation, which is why the intranasal route is used.8 The clinical Russian product is a ready-made solution, not a lyophilized powder, so the "reconstitution" guidance circulating on vendor sites pertains to research-chemical powders sold not for human use and falls outside any validated clinical protocol. No FDA-sanctioned US compounding or dosing standard exists.

How safe is Selank?

In the short Russian trials Selank was well tolerated, with the notable absence of benzodiazepine-type harms — no sedation, no psychomotor or attention impairment, and no dependence or withdrawal on discontinuation.1 The most common practical complaint is local nasal irritation from intranasal use.8 The principal safety caveat is the data gap: human studies are few and short, often days to about two weeks, so long-term safety, repeated-course safety and rare adverse events are essentially uncharacterized, and the entire human dataset is small and single-region.8 As a peptide of immune lineage that alters cytokine and interferon gene expression, immunogenicity and immune-modulatory off-target effects are a theoretical concern not excluded by existing trials.7 Animal data show Selank potentiates benzodiazepine (diazepam) anxiolysis, so caution is reasonable with other CNS-active agents.5 Pregnancy, lactation and pediatric use are unstudied and should be avoided; absence of documented harm is not evidence of safety. Research-chemical material carries separate impurity and mislabeling risks.

What is the FDA and WADA status in 2026?

Selank is a registered, approved anxiolytic in Russia, but it is not approved for any use by the US FDA, where it is sold only as a research chemical labeled not for human consumption.8 Its regulatory path in the US is specific: Selank acetate was placed in Category 2 (significant safety risk) of the FDA's interim 503A bulks list, then removed from Category 2 on September 27, 2024 because the nominator withdrew the nomination — explicitly not an FDA finding of safety or validity.10 The FDA subsequently recommended against, and PCAC voted against, adding the withdrawn peptides to the 503A bulks list, leaving Selank among "Other Bulk Drug Substances That May Present Significant Safety Risks" and not authorized for compounding.9 Following 2026 signals to revisit peptide compounding, several vendor trackers assert Selank is "back"; these claims are not reliable, because removal from Category 2 is not authorization, and Selank was not among the peptides scheduled for the July 23-24, 2026 PCAC meetings.11

For athletes the picture is conservative. Selank is not individually listed by name on the WADA Prohibited List, but as a non-approved pharmaceutical it falls under the catch-all category S0 for non-approved substances, which is prohibited at all times with no Therapeutic Use Exemption.12 The "research chemical" label confers no anti-doping protection; any tested athlete or military service member should treat Selank as banned.12 It is not a DEA-scheduled controlled substance.

Bottom line. Selank pairs a coherent, multi-strand mechanism with genuine — if small — human anxiolytic evidence in generalized anxiety disorder and neurasthenia, where it matched a benzodiazepine without sedation, cognitive dulling, dependence or withdrawal. From a root-cause perspective the enkephalin-stabilizing angle is appealing because it supports the body's own anti-stress peptide system rather than blunting it. But the evidence does not yet earn Grade A: there is no large independent placebo-controlled RCT or meta-analysis, near-absent long-term safety data, reliance on a single research lineage, and a messy US legal status — not FDA-approved, not compoundable, research-chemical only, and prohibited in sport. A reasonable, conservative read: promising and mechanistically interesting, under-proven by Western standards, and not appropriate for casual or unsupervised use. Regulatory facts here are current as of June 2026 and should be re-verified against the live FDA bulks page.